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The rapid emergence and spread of multi-resistant bacteria have created an urgent need for new anti-
microbial agents. We report here a series of amphipathic a,a-disubstituted b-amino amide derivatives
with activity against 30 multi-resistant clinical isolates of Gram-positive and Gram-negative bacteria,
including isolates with extended spectrum b-lactamase e carbapenemase (ESBL-CARBA) production. A
variety of halogenated aromatic side-chains were investigated to improve antimicrobial potency and
minimize formation of Phase I metabolites. Net positive charge and cationic character of the derivatives
had an important effect on toxicity against human cell lines. The most potent and selective derivative was
the diguanidine derivative 4e with 3,5-di-brominated benzylic side-chains. Derivative 4e displayed
minimum inhibitory concentrations (MIC) of 0.25e8 mg/mL against Gram-positive and Gram-negative
reference strains, and 2e32 mg/mL against multi-resistant clinical isolates. Derivative 4e showed also
low toxicity against human red blood cells (EC50> 200 mg/mL), human hepatocyte carcinoma cells
(HepG2: EC50> 64 mg/mL), and human lung fibroblast cells (MRC-5: EC50> 64 mg/mL). The broad-
spectrum antimicrobial activity and low toxicity of diguanylated derivatives such as 4e make them
attractive as lead compounds for development of novel antimicrobial drugs.
© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Modern society is facing the reality of a post-antibiotic era due
to the rapid emergence and spread of multi-resistant bacteria and
the lack of new antibiotics. European health authorities have esti-
mated that more than 33 000 patients die of infections caused by
multi-resistant bacteria each year, despite the use of considerable
financial resources of more than 1.5 billion Euros annually [1e3].ayer), morten.strom@uit.no
r Masson SAS. This is an open acceThe European Union started the Innovative Medicine Initiative
(IMI) in 2008, the largest public private partnership worldwide in
order to facilitate and accelerate the development of better medi-
cines [4]. Other initiatives have also been launched to tackle the
scientific, regulatory, and business challenges that hamper the
development of new antibiotics [5].
Aware of the increasing need of innovative antibiotics, our group
is developing and investigating amphipathic peptidomimetics such
as small a,a-disubstituted b-amino amides as potential antimicro-
bial agents, and for applications against microbial biofilms or can-
cer [6e11]. The structural design of these compounds is inspired by
cationic antimicrobial peptides (AMPs), which are a crucial part of
innate immunity in virtually every eukaryotic species [12]. Naturalss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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consist of 12e50 amino acid residues, and interact with bacteria
first by electrostatic interactions followed by disruption of bacterial
membrane structures [13]. The selectivity of cationic AMPs for
bacterial membranes is due to their higher content of negatively
charged cell wall components like teichoic acids, cardiolipin, and
phosphatidylglycerol, whereasmammalian cell membranes consist
of neutrally charged phospholipids and are stabilized by cholesterol
[12,14,15].
We have previously reported antimicrobial a,a-disubstituted b-
amino amides, which were designed based on the pharmacophore
model for short cationic AMPs suggesting that amphipathic pepti-
domimetics should contain two cationic charged groups and two
lipophilic bulky groups as important key features [10,16]. Other
examples of peptidomimetics or synthetic mimics of AMPs
(SMAMPs) exploring similar key features are reported by Teng et al.
[17], Ghosh et al. [18], Dewangan et al. [19], Murugan et al. [20], and
the groups of Svendsen [21,22], Bang [23], Tew [24e26], and
DeGrado [27,28]. The previously reported a,a-disubstituted b-
amino amides showed highest preference for Gram-positive bac-
teria, including antibiotic-resistant strains like methicillin resistant
Staphylococcus aureus (MRSA) and methicillin resistant Staphylo-
coccus epidermidis (MRSE), and biofilm producing strains [6,7]. The
mode-of-action involves membrane disruption and resembles
mechanisms reported for much larger AMPs [6,29]. Furthermore,
the a,a-disubstituted b-amino amides are stable against degrada-
tion by a-chymotrypsin and stable in aqueous solutions at pH 7.4
[8]. However, a,a-disubstituted b-amino amides are susceptible to
Phase I oxidations by murine liver microsomes [30]. Especially
electron rich aromatic (2-naphthyl)methyl side-chain groups can
be extensively oxidised. A strategy to reduce the possibility of Phase
I oxidations was therefore important to address in the present
design.
We hereby report the antimicrobial activity of a series of halo-
genated a,a-disubstituted b-amino amides (2aei), where the side-
chains were deactivated through halogenation to limit possible
Phase I metabolites (Fig. 1). We also included the synthetic mono-
amine nitrile precursors (1aei), a non-halogenated derivative 2j,
triamine derivatives (3d, 3e, 3g, 3i), and diguanidine derivatives
(4e, 4g, 4i) in the study. Our aim was to optimize antimicrobial
potency and reduce human cell toxicity through modifications of
overall lipophilicity, side-chain structures, and net positive charge
and basicity. The prepared derivatives were screened for antimi-
crobial activity against Gram-positive and Gram-negative reference
strains, and toxicity was evaluated against human red blood cells
(RBCs), human hepatocyte carcinoma cells (HepG2), and human
lung fibroblast cells (MRC-5). To further demonstrate their poten-
tial as antimicrobial lead compounds, the most promising de-
rivatives were tested against a panel of 30 multi-resistant clinical
isolates of MRSA, vancomycin resistant Enterococci (VRE), and
extended spectrum b-lactamase e carbapenemase (ESBL-CARBA)
producing Gram-negative isolates of Escherichia coli, Pseudomonas
aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii,
which are the main causatives of severe nosocomial infections [31].
Three diamine derivatives (2e, 2g, 2i) with representative haloge-
nated side-chains were also investigated for possible CYP450 Phase
1 metabolism using murine liver microsomes.
2. Results and discussion
2.1. Synthesis
Synthesis of the monoamine derivatives 1aei and the diamine
derivatives 2aej were carried out according to our optimized re-
ported method (Scheme 1) [32]. In brief, dialkylation of methylcyanoacetate with the appropriate benzyl or 1-naphthyl bromides
in dichloromethanewith 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
as base gave 5aei, and was followed by aminolysis with ethyl-
enediamine to give the monoamine derivatives 1aei. Reduction of
monoamines 1aei with either Raney-Nickel or ZnCl2/NaBH4 gave
the diamine derivatives 2aej and the triamine derivatives 3d, 3e, 3g
and 3i. Whereas reduction with ZnCl2/NaBH4 for 1.5 h resulted in
the diamine derivatives 2d, 2e, and 2i, longer reduction of the
amide functionality for 24 h gave the over-reduced triamine de-
rivatives 3d, 3e, 3g, and 3i. The diguanylated derivatives 4e, 4g and
4i were synthesized from the corresponding diamine salts 2 by
treatment with K2CO3 and N,N0-Di-Boc-1H-pyrazole-1-
carboxamidine in THF. The resulting Boc-protected diguanylated
derivatives were then deprotected with TFA in dichloromethane to
yield 4e, 4g and 4i.
Based on our previously reported method, reduction of the
fluorinated monoamine derivatives was performed with Raney-
Nickel providing 2aec, 2feh, and 2j, while the brominated
monoamine derivatives had to be reduced with ZnCl2/NaBH4 to
avoid de-bromination [32]. Surprisingly, Raney-Nickel reduction of
the 4-fluoronapht-1-yl substituted nitrile 1i resulted in de-
fluorination within 30min giving 2j and not the expected
diamine derivative 2i. Fortunately, the de-fluorination was avoided
by reducing 1i to 2i with ZnCl2/NaBH4 (1.5 h) similar to the
brominated nitriles. In general, the synthesis was scalable and
efficient involving only a few chromatographic purification steps.
2.2. Antimicrobial activity against bacterial reference strains and
toxicity against human cells
The monoamines 1, diamines 2, triamines 3, and diguanidines 4
(Fig. 1) were first evaluated for antimicrobial activity against Gram-
positive and Gram-negative reference strains (Table 1). Toxicity was
evaluated against human red blood cells (RBCs), human hepatocyte
carcinoma cells (HepG2), and human lung fibroblast cells (MRC-5)
(Table 1). The RBC results were also used for calculating a selectivity
index (SI) by dividing the RBC EC50 value with the minimum
inhibitory concentration (MIC) against S. aureus or E. coli. De-
rivatives with MIC 8 mg/mL and SI 10 were considered prom-
ising as lead compounds for further investigations. The results
revealed MIC values ranging from 0.25 to 4 mg/mL for the most
potent monoamine 1, diamines 2, triamines 3, and diguanidines 4
against Gram-positive and Gram-negative bacteria, but consider-
able variation was observed in haemolytic activity (RBC EC50:
23e>300 mg/mL) and human cell cytotoxicity (HepG2 or MRC-5
EC50: 4e>64 mg/mL), as discussed below. In the following sections
abbreviations used for side-chains are included in parentheses to
aid the discussion.
2.2.1. Correlation between antimicrobial activity and side-chain
size
Screening results for the monoamines 1a-i (Table 1) revealed a
strong correlation between antimicrobial activity and side-chain
size showing that the smallest fluorinated derivatives (1a-c) were
either inactive or much less potent than the larger bromo- and
trifluoromethylbenzyl derivatives (1d, 1fei). For the monoamines,
1i (4-F-1-Nal) displayed highest antimicrobial activity and was
potent against all bacterial reference strains tested (MIC: 2e32 mg/
mL). The trifluoromethylbenzyl derivatives 1feh showed compa-
rable antimicrobial activity against the bacterial reference strains
(MIC: 8e64 mg/mL) and were more potent than the brominated
derivatives 1dee. Derivative 1d (2-Br-Ph) displayed antimicrobial
activity against the Gram-positive strains and E. coli (MIC:
16e32 mg/mL), but was not active against P. aeruginosa. A high
antimicrobial activity was anticipated for 1e (3,5-Br-Ph) with larger
Fig. 1. Structures of the halogenated monoamine nitrile precursors 1ae1i, the target halogenated a,a-disubstituted b-amino amides 2ae2i and the de-fluorinated 2j, the reduced
triamines 3d, 3e, 3g and 3i, and the optimized diguanidine derivatives (4e, 4g, and 4i) investigated for antimicrobial activity. Diamine 2j was a result of de-fluorination during
synthesis of 2i. All derivatives are shown in their expected ionized state at pH 7.4.
M.H. Paulsen et al. / European Journal of Medicinal Chemistry 183 (2019) 111671 3side-chains, but 1e (3,5-Br-Ph) was poorly soluble in aqueous test
media, and we were therefore unable to detect any antimicrobial
activity (MIC: >64 mg/mL). For the smallest derivatives 1aec having
fluorobenzyl side-chains, 1a (2-F-Ph) displayed antimicrobial ac-
tivity against Corynebacterium glutamicum and E. coli, 1b (3,5-F-Ph)
was only active against C. glutamicum, whereas 1c (2,6-F-Ph) was
altogether inactive.
The antimicrobial monoamines 1 showed very low toxicity
against RBCs (EC50: 178 mg/mL), except for 1f (2-CF3-Ph) (EC50:
89 mg/mL) (Table 1). Haemolytic activity for 1i (4-F-1-Nal) was,however, difficult to determine because of precipitation when PBS
was added in the particular RBC assay. The highly potent derivative
1i (4-F-1-Nal) showed inappropriately high cytotoxicity against
HepG2 (EC50: 12 mg/mL) and MRC-5 cells (EC50: 4 mg/mL) and was
thereby not sufficiently selective for bacteria compared to human
cells to be of interest as a lead compound. The remaining mono-
amine derivatives were in general less cytotoxic than 1i (4-F-1-Nal)
against HepG2 and MRC-5 cells (EC50: 12e>64 mg/mL). Overall, the
combination of low antimicrobial activity, poor selectivity (i.e. low
SI except for 1g (3,5-CF3-Ph)), and limited aqueous solubility made
Scheme 1. Synthesis of halogenated monoamine derivatives (1aei), a,a-disubstituted
b-amino amides (i.e. diamines 2aej), triamines (3d, 3e, 3g, 3i), and diguanidines (4e,
4g, 4i) investigated for antimicrobial activity. The series included also the de-
fluorinated diamine derivative 2j from the first attempted synthesis of 2i [32]. Reac-
tion condition: a) AreCH2eBr, DBU, CH2Cl2, r.t. b) Ethylenediamine (solvent), r.t.,
0.5e24 h. c) For synthesis of 2aec, 2feh, and 2j: 1) Raney-Nickel/H2(g), Boc2O, MeOH
or EtOAc, 45 C (18 h), 1 or 8e10 bar, 2) 1.33M HCl in dioxane, 60 C (2 h). d) For
synthesis of 2d, 2e, 2i: ZnCl2/NaBH4, THF, reflux (1.5 h). e) For synthesis of 3d, 3e, 3g,
3i: ZnCl2/NaBH4, THF, reflux (24 h). f) K2CO3, N,N0-Di-Boc-1H-pyrazole-1-
carboxamidine, THF, r.t. 48e72 h.
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pounds. The limited water solubility may be explained by this se-
ries having only a single ionisable group to make up for the
lipophilic contribution of the side-chains.2.2.2. Increasing net positive charge and increased antimicrobial
potency
Increasing the net positive charge gave a general improvement
in antimicrobial activity, as observed for the diamines 2, and also
improved aqueous solubility. The most potent and broad-spectrum
derivatives were the bulky side-chain derivatives 2e (3,5-Br-Ph), 2g
(3,5-CF3-Ph), and 2i (4-F-1-Nal) (MIC: 1e8 mg/mL). The effect of
side-chain size on antimicrobial activity was thereby further
emphasized, as well as the advantage of increasing the net positive
charge. The de-fluorinated derivative 2j (1-Nal) displayed similar
antimicrobial activity against the Gram-positive strains (MIC:
2e4 mg/mL) as its fluorinated analogue 2i (4-F-1-Nal), but 2j (1-Nal)
was less potent against the Gram-negative bacteria (MIC: 16 mg/
mL).
The previously reported derivative 2h (4-CF3-Ph) was in general
more potent than the analogous derivative 2f (2-CF3-Ph) revealing
a positional effect of the CF3-substituent [6]. As a smaller bromi-
nated analogue of 2f (2-CF3-Ph), derivative 2d (2-Br-Ph) was also
less potent and showed low antimicrobial activity against all
reference strains (MIC: 64 mg/mL) except against C. glutamicum
(MIC: 8 mg/mL). For the smallest fluorinated derivatives 2aec,
detectable antimicrobial activity was only observed for 2b (3,5-F-
Ph) against C. glutamicum (MIC: 64 mg/mL). The results for thediamines 2 demonstrated a favourable antimicrobial effect by
increased cationic charge (þ2) and bulky steric demanding side-
chains, and especially in order to ensure high activity against the
Gram-negative bacteria E. coli and P. aeruginosa.
Toxicity against human RBCs of the most antimicrobial active
derivatives 2e (3,5-Br-Ph), 2g (3,5-CF3-Ph) and 2i (4-F-1-Nal) was
higher (EC50: 48e74 mg/mL) than for the other diamines 2 (EC50:
90e312 mg/mL). Derivative 2i (4-F-1-Nal) was least haemolytic,
followed by 2e (3,5-Br-Ph) and 2g (3,5-CF3-Ph), although the dif-
ferences between these were minimal. The high antimicrobial po-
tencies of 2e, 2g and 2i resulted in SI of 12e29, which was an
improvement compared to the antimicrobial monoamines 1
(Table 1). Cytotoxicity of 2e (3,5-Br-Ph), 2g (3,5-CF3-Ph) and 2i (4-F-
1-Nal) against HepG2 (EC50: 11e13 mg/mL) and MRC-5 (EC50:
4e17 mg/mL) cells was, however, unsatisfactory and revealed
limited selectivity for bacteria compared to human cells. Derivative
2j (1-Nal), which was highly potent against the Gram-positive
strains, was less toxic against RBCs (EC50: 90 mg/mL) resulted in a
SI of 23 with respect to S. aureus. Toxicity against MRC-5 cells (EC50:
9 mg/mL) was at the same level as for the most potent diamines and
therefore not satisfactory. The previously reported derivative 2h (4-
CF3-Ph) was practically non-haemolytic (EC50: 289 mg/mL) and
resulted in high SI of 18e36. This derivative has not been tested
against HepG2, but showed cytotoxicity against MRC-5 cells (EC50:
16 mg/mL). Its CF3-positional analogue 2f (2-CF3-Ph) was less toxic
against RBCs (EC50: 312 mg/mL), HepG2 cells (EC50: 45 mg/mL), and
MRC-5 cells (EC50: 42 mg/mL) in accordance with having lower
antimicrobial activity. The lowantimicrobial activity of 2d (2-Br-Ph)
agreedwith this derivative being non-haemolytic (EC50 271 mg/mL),
and exhibiting low cytotoxicity against HepG2 (EC50: 48 mg/mL) and
MRC-5 (EC50: 56 mg/mL) cells. The results thereby demonstrated a
structural correlation between antimicrobial activity and toxicity
against human cells for the diamines 2. When evaluating overall
broad-spectrum antimicrobial activity and human cell toxicity of
the diamines 2, the three derivatives 2e (3,5-Br-Ph), 2g (3,5-CF3-Ph)
and 2i (4-F-1-Nal) were the most promising candidates from this
series, although a higher SI would have been favoured.
2.2.3. Increased haemolytic activity by reduction of the amide
group
In an attempt to reduce human cell toxicity, we prepared a small
series of triamine derivatives 3d (2-Br-Ph), 3e (3,5-Br-Ph), 3g (3,5-
CF3-Ph), and 3i (4-F-1-Nal) by over-reduction of the corresponding
diamine 2 precursors with ZnCl2/NaBH4. This reduction of the
amide group allowed us to investigate the influence of an addi-
tional amino group, and potentially increased net positive charge,
for antimicrobial potency and toxicity (Fig. 1 and Scheme 1). The
side-chain motifs were inspired by the most potent diamine de-
rivatives 2e (3,5-Br-Ph), 2g (3,5-CF3-Ph), and 2i (4-F-1-Nal) and the
less potent 2d (2-Br-Ph). The results showed that 3e (3,5-Br-Ph), 3g
(3,5-CF3-Ph), and 3i (4-F-1-Nal) displayed high and broad-
spectrum antimicrobial activity (MIC: 1e4 mg/mL) against all the
reference strains. The antimicrobial potencies of these triamine
derivatives were thereby in the same range as their diamine
counterparts, as observed by pairwise comparingMIC values for 2e/
3e (3,5-Br-Ph), 2g/3g (3,5-CF3-Ph), and 2i/3i (4-F-1-Nal). Derivative
3d (2-Br-Ph) showed furthermore a fourfold increase in potency
against all strains (MIC: 2e16 mg/mL) compared to its diamine
counterpart 2d (2-Br-Ph) (MIC: 8e64 mg/mL). The haemolytic ac-
tivity was, however, more than 2-fold higher for the triamine de-
rivatives 3e (3,5-Br-Ph), 3g (3,5-CF3-Ph), and 3i (4-F-1-Nal)
compared to the diamine derivatives, whereas cytotoxicity against
HepG2 andMRC-5 was less affected. An exceptionwas the triamine
derivative 3d (2-Br-Ph), which showed only a small increase in RBC
toxicity (EC50: 209 mg/mL), but a more drastic increase in HepG2
Table 1
Antimicrobial activity (MIC in mg/mL) against bacterial reference strains, haemolytic activity against human RBC (EC50 in mg/mL), and toxicity against human HepG2 and MRC-
5 cells (EC50 in mg/mL).
Antimicrobial activity (MIC) Toxicity (EC50) Selectivity index (SI)a
Entry Mw S. aureus C. glutamicum E. coli P. aeruginosa RBC HepG2 MRC-5 RBC/S. aureus RBC/E. coli
1a 379.84b >64 16 64 >64 190 >64 e e 3
1b 415.82b >64 32 >64 >64 208 >64 e e e
1c 415.82b >64 >64 >64 >64 e >64 e e e
1d 501.65b 16 32 32 >64 211 26 32 13 7
1e 659.44b >64 >64 >64 >64 e e e e e
1f 479.85b 16 8 16 32 89 24 27 6 6
1g 615.85b 16 8 32 64 282 20 12 18 9
1h 479.84b 32 8 16 64 178 23 18 6 11
1i 479.95b 4 2 4 32 >500f 12 4 -f -f
2a 575.46c >64 >64 >64 >64 e >64 e e e
2b 611.44c >64 64 >64 >64 228 >64 e e e
2c 611.44c >64 >64 >64 >64 e >64 e e e
2d 697.27c 64 8 64 64 271 48 56 4 4
2e 855.06c 2 2 4 4 58 13 17 29 15
2f 675.47c 32 8 32 64 312 45 42 10 10
2g 656.34d 4 1 4 4 48 11 11 12 12
2h 675.47c 8 4 16 32 289 e 16 36 18
2i 675.58c 4 2 4 8 74 12 4 19 19
2j 639.60c 4 2 16 16 90 e 9 23 6
3d 528.15d 16 2 16 16 209 18 8 13 13
3e 841.08c 2 1 4 4 24 12 15 12 6
3g 797.49c 4 1 4 4 23 7 14 6 6
3i 661.59c 2 1 4 4 27 12 9 14 7
4e 939.14c 1 0.25 8 4 206 >64 >64 206 26
4g 895.55c 2 0.5 4 4 201 >64 >64 101 50
4i 759.66c 2 0.5 16 8 329 e e 165 21
OTCe 460.434 0.65 0.65 2.5 20 e >64 e e e
Bacterial reference strains: Staphylococcus aureus ATCC 9144; Corynebacterium glutamicum ATCC 13032; Escherichia coli ATCC 25922, and Pseudomonas aeruginosa PA01, DSM
19880 (ATCC 15692).
-: not determined.
a Selectivity index (SI) calculated as the RBC EC50 value divided by the MIC values against S. aureus or E. coli.
b Mw including 1 equiv. HCl.
c Mw including 2 equiv. CF3COOH as determined by F NMR for 2g, 3g, 4g.
d Mw including 2 equiv. HCl.
e Reference antibiotic: Oxytetracycline hydrochloride.
f Precipitation observed when PBS was added in the RBC assay. The SI was therefore not calculated for 1i.
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Introduction of an additional amino group, and potential increased
net positive charge, resulted in increased antimicrobial activity, but
a worsening of human cell cytotoxicity.2.2.4. Reduction of human cell toxicity by diguanylation
Encouraged by the high antimicrobial activities achieved, we
were still challenged by the increased human cell toxicity displayed
by the triamines 3. In an effort to reduce human cell toxicity we
therefore chose to increase the basicity by guanylating the amino
groups of the three most promising diamines 2e, 2g, and 2i to
provide the corresponding diguanylated derivatives 4e (3,5-Br-Ph),
4g (3,5-CF3-Ph), and 4i (4-F-1-Nal) (Scheme 1 and Table 1).
The results for the diguanidines 4 showed a positive effect that
introducing two guanidine groups both increased antimicrobial
activity and reduced human cell toxicity. The diguanidines 4 were
also more potent against Gram-positive bacteria (MIC: 0.25e2 mg/
mL) than any of the previous series, and 4e (3,5-Br-Ph) and 4g (3,5-
CF3-Ph) showed also good activity against the Gram-negative bac-
teria (MIC: 4e8 mg/mL). It may be noted that 4i (4-F-1-Nal) showed
reduced potency against the Gram-negative bacteria compared to
the corresponding triamine derivative 3i (4-F-1-Nal). Importantly,
derivatives 4e (3,5-Br-Ph), 4g (3,5-CF3-Ph) and 4i (4-F-1-Nal) were
all essentially non-haemolytic (EC50:>200 mg/mL) and displayed no
measurable cytotoxicity against human HepG2 and MRC-5 cells
within the concentration range tested (EC50: >64 mg/mL). Together,
the high antimicrobial activity and lack of toxic effects againsthuman cells resulted in the highest achieved SI values for 4e (3,5-
Br-Ph), 4g (3,5-CF3-Ph), and 4i (4-F-1-Nal). These were in the
range of SI: 101e206 with respect to RBC/S. aureus, and SI: 21e50
with respect to RBC/E. coli.
The reason for the observed lower toxicity of the diguanidines 4
compared with the diamines 2 is not clear. Possible explanations
could be: (i) the guanidine derivatives were not able to interact
with potential intracellular targets due to decreased diffusion
across cell membranes because of higher basicity of guanidine
groups (calculated pKa 11.3±0.9) compared to amine groups
(calculated pKa 9.3e9.6±0.8), (ii) the diguanidines cause a different
cell membrane damaging effect, or (iii) different targets in bacteria
and human cells are involved explaining the differences in anti-
microbial activity and toxicity. In this respect, the group of Bunker
has recently used in-silico molecular dynamics simulations to
investigate the mechanism of action of previously reported
amphipathic a,a-disubstituted b-amino amide derivatives (or b2,2-
amino acid derivatives) [29]. In their studies, they show that the
derivatives locate to the lipid-water interface of model membranes,
and that the conformation of the lipophilic side-chains differs
based on the structure of the hydrophilic groups. The conformation
of the lipophilic side-chains also differs depending on interaction
with model bacterial or eukaryotic membranes, which can explain
variances in antimicrobial efficacy and selectivity.
We have calculated the pKa values in-silico of monoamine 1e,
diamine 2e, triamine 3e, and diguanidine 4e to determine the net
positive charge at physiological pH 7.4 using the Epik software [33].
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alter the pKa of the second amine or guanidine group present in the
molecule. The calculations showed that the effect of protonation of
a neighbouring group was only relevant for the triamine 3e, in
which the secondary amino group was neutral at pH 7.4 whereas
both the primary amino groups were charged. Thus, at physiolog-
ical pH 7.4 the monoamine 1e has a net positive charge of þ1, while
diamine 2e, triamine 3e, and diguanidine 4e all are expected to
have a net charge of þ2. This was also in accordance with F NMR
analysis of the fluorinated series 2g, 3g, and 4g (Supporting
information).
A summary of the most important structure-activity relation-
ships (SAR) found for the a,a-disubstituted b-amino amide de-
rivatives is shown in Fig. 2.
2.2.5. Comparison with reference antibiotic
Oxytetracycline hydrochloride was included as reference anti-
biotic, and displayed MIC values from 0.65 to 2.5 mg/mL against
S. aureus, C. glutamicum and E. coli, and a MIC of 20 mg/mL against
P. aeruginosa (Table 1). These results demonstrated that our most
potent derivatives were close to oxytetracycline with respect to
antimicrobial activity against the Gram-positive reference strains
and E. coli.
2.3. Antimicrobial activity against 30 multi-resistant clinical
isolates
The most potent derivatives prepared were further screened
against 30 multi-resistant clinical isolates of Gram-positive
(S. aureus and Enterococcus faecium) [34e37] and Gram-negative
bacteria (E. coli, P. aeruginosa, K. pneumoniae, and A. baumannii),
including isolates with extended spectrum b-lactamase e carba-
penemase (ESBL e CARBA) production and colistin resistance
(Table 2). The panel of multi-resistant Gram-negative clinical iso-
lates originated from the strain collection at The Norwegian Na-
tional Advisory Unit on Detection of Antimicrobial Resistance (K-
res) [38e40].
The monoamine derivative 1g (3,5-CF3-Ph) was selected based
on its favourable activity and advantageous RBC toxicity profile
among the monoamines 1. The results showed that 1g (3,5-CF3-Ph)
displayed antimicrobial activity against the multi-resistant Gram-
positive isolates S. aureus and E. faeciumwith MIC values from 8 to
32 mg/mL, but no activity was observed against the multi-resistant
Gram-negative clinical isolates within the concentration rangeFig. 2. Summary of SAR for series 2, 3 and 4 for assuring high antimicrobial activity
and low toxicity against human cell lines. Shown in the figure is a hybrid compound e
all tested compounds had two identical lipophilic side-chains and were thereby
achiral. The effect of side-chain size was also demonstrated by similar antimicrobial
potency and toxicity of derivatives with either two 4-F-1-Nal (2i, 3i, 4i) or two 3,5-CF3-
Ph (2g, 3g, 4g) side-chains. *Cationic guanidine groups ensured both high antimicro-
bial activity and low toxicity against RBC, HepG2 and MRC-5 cells.tested (up to 32 mg/mL).
Five diamine derivatives were tested; 2e (3,5-Br-Ph), 2f (2-CF3-
Ph), 2g (3,5-CF3-Ph), 2h (4-CF3-Ph), and 2i (4-F-1-Nal). As observed
against the bacterial reference strains (Table 1), 2e (3,5-Br-Ph), 2g
(3,5-CF3-Ph), and 2i (4-F-1-Nal) were the overall most potent de-
rivatives and displayed high broad-spectrum activity with MIC
values as low as 4e8 mg/mL against individual multi-resistant iso-
lates of S. aureus, E. faecium and K. pneumoniae. The only exception
was against P. aeruginosa (MIC: 32 mg/mL). Derivative 2f (2-CF3-
Ph) and our reference derivative 2h (4-CF3-Ph) were least potent,
but MIC values of 8e16 mg/mL were achieved for 2h (4-CF3-Ph)
against all but one of the Gram-positive E. faecium isolates.
High broad-spectrum activity was demonstrated by the tri-
amine derivatives against the multi-resistant clinical isolates. De-
rivatives 3e (3,5-Br-Ph), 3g (3,5-CF3-Ph), and 3i (4-F-1-Nal)
displayed MIC values of 4e16 mg/mL against multi-resistant
S. aureus, E. faecium, E. coli, K. pneumoniae, and A. baumannii, and
MIC values of 16e32 mg/mL against isolates of P. aeruginosa. The
triamine derivatives were also highly potent against the multi-
resistant isolates K. pneumoniae K47-25, K. pneumoniae 50531633,
and A. baumannii K63-58, which are resistant to the last-resort
cationic antibiotic colistin (Prof. Ørjan Samuelsen, personal
communication, K-Res/University Hospital of North Norway - UNN).
Derivative 3d (2-Br-Ph) was less potent, but displayed comparable
antimicrobial activity as the promising diamine derivatives 2e (3,5-
Br-Ph), 2g (3,5-CF3-Ph), and 2i (4-F-1-Nal).
The optimized diguanidine derivative 4e (3,5-Br-Ph) showed
broad-spectrum antimicrobial activity, and was especially potent
against clinical isolates of S. aureus, E. faecium, and E. coli with MIC
values of 2e8 mg/mL. Derivative 4e (3,5-Br-Ph) showed also good
activity against individual isolates of P. aeruginosa (MIC: 4e8 mg/
mL) for all but two exceptions (MIC: 16 mg/mL against
K. pneumoniae and A. baumannii). The diguanidine derivatives 4g
(3,5-CF3-Ph) and 4i (4-F-1-Nal) showed acceptable antimicrobial
activity against S. aureus and E. faecium, but were much less potent
against the Gram-negative clinical isolates (MIC: 16 ->32 mg/mL).
From these studies it could be concluded that the diguanidine de-
rivative 4e (3,5-Br-Ph) was a highly potent lead compound against
multi-resistant clinical isolates of Gram-positive and Gram-
negative bacteria, and also favourably with respect to human cell
line toxicity.
2.4. Phase I metabolism
Introduction of fluorine-atoms into chemical scaffolds is a
common strategy in drug development to prevent hepatic CYP450
Phase I oxidation of aromatic groups [41]. As we have reported
previously, a,a-disubstituted b-amino amides are susceptible to
Phase I oxidations, especially derivatives having electron rich (2-
naphthyl)methyl side chains [30]. This study revealed extensive
metabolism, in which the main metabolites are hydroxylation of
the aromatic (2-naphthyl)methyl side-chains. For a,a-disubstituted
b-amino amides with 4-tert-butylbenzyl side chains the tert-butyl
group is oxidised, whereas the side chain of our previously reported
halogenated 2h (4-CF3-Ph) is inert to Phase I oxidation [6,30]. He-
patic CYP450 enzymes are membrane-associated and metabolise
preferably lipophilic substrates and to a minor extent hydrophilic
substrates. To further investigate the effect of halogenated sub-
stituents on metabolic stability, three representatives of haloge-
nated diamine derivatives 2e (3,5-Br-Ph), 2g (3,5-CF3-Ph), and 2i
(4-F-1-Nal) were selected for Phase 1 metabolism studies using
murine liver microsomes. The diamine derivatives were preferred
for side chain metabolism studies in place of the more hydrophilic
diguanidines 4.
The results confirmed our expectations for the halogenated
Table 2
Antimicrobial activity (MIC in mg/mL) of the most potent derivatives against 30 multi-resistant clinical isolates.
Multi-resistant isolates 1g 2e 2f 2g 2 h 2i 3d 3e 3g 3i 4e 4g 4i ESBL-CARBAa
S. aureus N315 >32 8 >32 16 >32 16 8 4 8 4 2 4 4
S. aureus NCTC 10442 32 8 >32 16 >32 8 16 4 8 4 2 8 4
S. aureus strain 85/2082 32 8 >32 16 >32 8 8 8 8 4 2 8 4
S. aureus strain WIS 16 16 >32 16 >32 16 8 8 8 4 2 8 4
S. aureus IHT 99040 16 16 32 8 >32 16 8 8 8 8 2 8 4b
E. faecium 50673722 16 8 32 8 16 16 16 4 4 4 4 8b 16
E. faecium 50901530 16 8 32 4 16 16 16 4 8 4 4 4b 4b
E. faecium K36-18 8 8 >32 8 16 16 16 8 8 4 4 8b 16
E. faecium 50758899 8 8 >32 4 32 8 16 4 8 4 4 8b 16
E. faecium TUH50-22 8 8 >32 8 8 8 16 4 4 4 2 4 8b
E. coli 50579417 >32 8 >32 16 >32 8 16 16 8 8 8b 32b 32 OXA-48
E. coli 50639799 >32 16 >32 16 >32 16 16 8 8 8 8b 16b 32 VIM-29
E. coli 50676002 >32 16 >32 16 >32 8 16 8 8 8 8b 32b 32b NDM-1
E. coli 50739822 >32 8 >32 16 32 16 16 8 8 4 8b 32b 32b NDM-1
E. coli 50857972 >32 8 >32 8 32 8 16 8 8 8 8b 32b 32 IMP-26
P. aeruginosa K34-7 >32 >32 >32 >32 >32 >32 32 16 32 16 16b 32 >32 VIM-2
P. aeruginosa K34-73 >32 32 >32 32 >32 32 32 16 32 16 16 16 >32 VIM-4
P. aeruginosa K44-24 >32 32 >32 >32 >32 32 32 16 32 16 16 32 >32 IMP-14
P. aeruginosa 50692172 >32 >32 >32 32 >32 >32 32 32 16 16 8b 32b >32 NDM-1
P. aeruginosa 50692520 >32 >32 >32 >32 >32 >32 16 32 32 16 4 16 >32 VIM
K. pneumoniae K47-25c >32 16 >32 32 >32 32 16 8 16 8 32b >32 >32 KPC-2
K. pneumoniae K66-45 >32 32 >32 32 >32 8 16 8 8 8 16b >32 >32 NDM-1
K. pneumoniae 50531633c >32 16 >32 16 32 8 16 8 8 4 16 >32 >32 NDM-1 þOXA-181
K. pneumoniae 50625602 >32 8 >32 16 32 8 16 16 8 8 16b >32 >32 OXA-245
K. pneumoniae 50667959 >32 16 >32 16 32 8 16 16 8 8 16 >32 >32 VIM-1
A. baumannii K12-21 >32 32 >32 8 >32 32 16 16 8 8 16b >32 >32 OXA-58
A. baumannii K44-35 >32 32 >32 16 >32 >32 16 8 8 8 16b >32 >32 OXA-23
A. baumannii K47-42 >32 16 >32 16 >32 16 16 16 8 16 16b >32 >32 OXA-23
A. baumannii K55-13 >32 16 >32 16 >32 32 16 8 8 16 16b >32 >32 OXA-24
A. baumannii K63-58c >32 32 >32 8 >32 16 16 8 8 8 16b >32 >32 OXA-23
a ESBL-CARBA: Extended spectrum b-lactamase e carbapenemase producing isolates. OXA, oxacillinase; VIM, Verona integron-encoded metallo-b-lactamase; NDM, New
Delhi metallo-b-lactamase; IMP, imipenem-type carbapenemase; KPC, K. pneumoniae carbapenemase.
b Precipitation observed as described in the methods section.
c Clinical isolates resistant to the antibiotic colistin.
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phase high-performance liquid chromatography - mass spectrom-
etry (RP-HPLC-MS) analysis was unable to detect formation of any
metabolites resulting from, e.g., deamination, oxidation (hydrox-
ylation), or dioxidation (dihydroxylation) for up to 3 h of incubation
(results not presented). For the (4-fluoronapht-1-yl)methyl deriv-
ative 2i (4-F-1-Nal) approx. 9% was metabolised after 3 h of incu-
bation (Fig. 3). Three different Phase I oxidised metabolites were
detected from 2i (4-F-1-Nal) as shown in Scheme 2. The main
metabolite resulted from hydroxylation of one of the side-chains in
2i (4-F-1-Nal) counting for approx. 7% of the total amount of me-
tabolites formed after 3 h. We were not able to determine the exactFig. 3. Formation of Phase I metabolites from 2i (4-F-1-Nal) over time by oxidation in
murine liver microsomes (y-axis: percentage of formed metabolites from 2i).
Scheme 2. Phase I metabolites formed from 2i (4-F-1-Nal) by oxidation in murine liver
microsomes. Dioxidised metabolites (lower; right) may involve dioxidation on one of
the 2i (4-F-1-Nal) side-chains or oxidation on both side-chains.position of oxidation, but a total of four different isomeric metab-
olites were detected, as observed by RP-HPLC-MS analysis. The
analysis also revealed small amounts of a dihydrodiol metabolite,
and four different dioxidised metabolites with varying retention
times (Scheme 2). However, due to the low abundance of the
dioxidised metabolites, we were unable to distinguish between
dioxidation on one of the 2i (4-F-1-Nal) side chains from oxidation
of both side chains.
Based on these results, it was evident that the halogenated
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amides provided protection against Phase I oxidations for 2e (3,5-
Br-Ph) and 2g (3,5-CF3-Ph), and also substantially lowered the
formation of Phase I metabolites from 2i (4-F-1-Nal) compared to
previously reported derivatives with (2-naphthyl)methyl side-
chains [30]. Based on the presumed membrane disrupting mech-
anism of action, oxidation of the aromatic side chains is likely to
result in metabolites with reduced antimicrobial potency because
of reduced overall lipophilicity. This is supported by the low po-
tency of a previously reported a,a-disubstituted b-amino amide
derivative with 3,5-dimethoxy benzylic side-chains [8].
3. Conclusions
Design of small amphipathic peptidomimetics is an attractive
strategy for developing novel antimicrobial agents resembling the
unique mode of action of larger AMPs that disrupt bacterial
membranes. Inspired by nature, synthesis of small peptidomi-
metics offer great possibilities for developing new compounds with
high antimicrobial activity and favourable pharmacokinetic prop-
erties (ADMETox), such as improved proteolytic stability and
tolerable toxicity. We have through a systematic study and
screening against bacterial reference strains and 30 multi-resistant
clinical isolates shown that halogenated a,a-disubstituted b-amino
amides, amines and guanidines are promising antimicrobial agents,
also against challenging Gram-negative multi-resistant clinical
isolates. The diguanidine derivative 4e (3,5-Br-Ph) showed excep-
tional high antimicrobial activity against both bacterial reference
strains and multi-resistant clinical isolates, and no major in vitro
human cell toxicity. Studies with liver microsomes also showed
that the lipophilic side-chains of 4e (3,5-Br-Ph) were not suscep-
tible for Phase I oxidations andmay thereby provide highmetabolic
stability in vivo. The study has surveyed in total nine different
halogenated aromatic side-chains that can have beneficial effects
also in other antimicrobial peptidomimetics and AMPs as lipophilic
constituents. Especially the halogenated lipophilic groups e (3,5-Br-
Ph), g (3,5-CF3-Ph), and i (4-F-1-Nal) (Scheme 1) may be worth
implementing in SAR studies to improve antimicrobial potency,
modify human cell toxicity, and improve pharmacokinetic prop-
erties such as in vivo stability.
4. Experimental section
4.1. Chemicals and equipment
All reagents and solvents were purchased from commercial
sources and used as supplied unless otherwise stated. Anhydrous
THF was prepared by storage over 4 Å molecular sieves. Raney-
Nickel was bought from Sigma Aldrich (CAS no. 7440-02-0, 2800,
slurry, in H2O, active catalyst). Reactions were monitored by thin-
layer chromatography (TLC) with Merck pre-coated silica gel
plates (60 F254). Visualization was accomplished with either UV
light or by immersion in potassium permanganate or phospho-
molybdic acid (PMA) followed by light heating with a heating gun.
Purification of reactions was carried out by chromatography using a
reversed-phase (RP) C18 column preloaded on a Samplet® cartridge
belonging to a Biotage SP-1 system. Analytical RP-HPLC was carried
out on a Waters 2695 Separations Module equipped with an
XBridge™ C18 5 mm, 4.6mm 250mm column and analysed at
wavelengths 214 and 254 nm with a Waters 996 PDA detector
spanning from wavelengths 210e310 nm. The derivatives were
eluted with a mobile phase consisting of water and acetonitrile,
both containing 0.1% TFA. The gradient started at 10% acetonitrile
(3min), followed by a linear gradient to 90% acetonitrile over
17min. The flow rate was 1mLmin1. NMR spectra were obtainedon both a 400MHz Bruker Avance III HD equipped with a 5mm
SmartProbe BB/1H (BB¼ 19F, 31Pe15N) and a 600MHz Varian
Inova spectrometer (Agilent, St. Clara, CA, USA) equipped with an
inverse HCN probe with cryogenic enhancement for 1H. Data are
represented as follows: chemical shift, multiplicity (s¼ singlet,
d¼ doublet, t¼ triplet, q¼ quartet, p¼ pentet, h¼ heptett,
m¼multiplet), coupling constant (J, Hz) and integration. Chemical
shifts (d) are reported in ppm relative to the residual solvent peak
(CDCl3: dH 7.26, and dC 77.16; Methanol-d4: dH 3.31 and dC 49.00,
DMSO‑d6: dH 2.50 and dC 39.52). Positive ion electrospray ionization
mass spectrometry (ESI-MS) was conducted on a Thermo electron
LTQ Orbitrap XL spectrometer with an Electrospray ion source
(ION-MAX) - Thermo scientific.
4.2. Synthesis of test derivatives
Synthesis and spectroscopic data for derivatives 5a-h, 1a-h, and
2a-h have previously been published by our group [32]. Com-
pounds 1aei were evaluated as HCl salts obtained from treatment
with HCl in ether. All compounds tested were >95% pure as
determined by analytical HPLC, with exception of 2jwhich was 85%
pure. 1-(Bromomethyl)-4-fluoronaphthalene was synthesized ac-
cording to literature procedures from 4-fluoro-1-naphthoic acid
[42].
Preparation of ZnCl2/NaBH4 reducing agents. The reducing agent
was prepared by stirring ZnCl2 (1 equiv., 1.15 g) and NaBH4 (2 equiv.,
0.68 g) in dry THF (40mL) overnight.
Methyl 2-cyano-3-(4-fluoro-1-naphthyl)-2-[(4-fluoro-1-
naphthyl)methyl]propionate (5i). Methyl 2-cyanoacetate
(8.53mmol, 0.753mL) was dissolved in CH2Cl2 (40mL, prefiltered
through K2CO3), cooled to 0 C, added DBU (2.62mL, 2.00 equiv.),
and stirred for 2min. 1-(Bromomethyl)-4-fluoronaphthalene
(4.20 g, 2.05 equiv.) was added in small portions to avoid increase
in temperature. The reaction was left to stir at r.t. until completion
was indicated by TLC (1:4 EtOAc/toluene). After completion, the
reaction was quenched with water and extracted with EtOAc. The
organic phase was washed with water (3 times) and brine, dried
over Na2SO4, filtered and evaporated to dryness. To remove residual
EtOAc, chloroformwas added and re-evaporated. MeOH was added
to precipitate the crude. The resulting solid was recrystallized in
MeOH to give the title derivative (5i) as light brown crystals (3.41 g,
96%). 1H NMR (400MHz, CDCl3) d 8.16 (d, J¼ 7.9 Hz, 2H), 8.06 (d,
J¼ 8.3 Hz, 2H), 7.71e7.53 (m, 4H), 7.49 (dd, J¼ 8.0, 5.4 Hz, 2H), 7.14
(dd, J¼ 10.0, 8.0 Hz, 2H), 3.86 (dAB, J¼ 14.4 Hz, 2H), 3.70 (dAB,
J¼ 14.4 Hz, 2H), 3.37 (s, 3H). 13C NMR (101MHz, CDCl3) d 169.0,
158.6 (d, J¼ 253.0 Hz), 133.4 (d, J¼ 4.5 Hz), 128.4 (d, J¼ 8.6 Hz),
127.1, 126.2 (d, J¼ 4.6 Hz), 126.1 (d, J¼ 1.9 Hz), 123.9 (d, J¼ 15.9 Hz),
123.7 (d, J¼ 2.6 Hz), 121.1 (d, J¼ 6.0 Hz), 118.6, 108.9 (d, J¼ 20.2 Hz),
53.4, 52.5, 38.3. HRMS-ESI m/z: C26H19F2KNO2 [MþK]þ calculated
for 454.1013, found: 454.1020.
3-(2-Aminoethylamino)-2,2-bis[(4-fluoro-1-naphthyl)methyl]-3-
oxopropiononitrile (1i). The reaction was performed under N2.
Methyl 2-cyano-3-(4-fluoro-1-naphthyl)-2-[(4-fluoro-1-naphthyl)
methyl]propionate (5i) (6.97mmol, 2.89 g) was added ethylenedi-
amine (20mL) and stirred at room temperature for 24 h and
completion was indicated by TLC (1:4 EtOAc/toluene). After
completion, the reaction mixture was cooled on ice and water was
added to the reaction mixture until precipitation occurred. The
product was filtered off, washed carefully with water and dried
under vacuum to give the title derivative (1i) as light brownpowder
(2.47 g, 80%). 1H NMR (400MHz, Methanol-d4) d 8.31 (dt, J¼ 8.1,
1.7 Hz, 2H), 8.10 (dd, J¼ 8.0, 1.6 Hz, 2H), 7.71e7.46 (m, 6H), 7.16 (dd,
J¼ 10.4, 8.0 Hz, 2H), 3.97 (dAB, J¼ 14.2 Hz, 2H), 3.83 (dAB,
J¼ 14.2 Hz, 2H), 2.87 (t, J¼ 6.5 Hz, 2H), 2.22 (t, J¼ 6.5 Hz, 2H). 13C
NMR (101MHz, CDCl3) d 166.7, 158.8 (d, J¼ 252.9 Hz), 133.8 (d,
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J¼ 1.9 Hz), 124.4 (d, J¼ 2.7 Hz), 124.1 (d, J¼ 15.9 Hz), 121.3 (d,
J¼ 6.0 Hz), 120.6, 109.1 (d, J¼ 20.1 Hz), 53.6, 42.9, 40.1, 38.2. HRMS-
ESI: C27H24F2N3O [MþH]þ calculated for 444.1882, found: 444.1883.
3-Amino-1-(2-aminoethylamino)-2,2-bis[(4-fluoro-1-naphthyl)
methyl]-1-propanone (2i). The nitrile 1i (0.11mmol, 0.050 g, 1
equiv.) was dissolved in ZnCl2/NaBH4 reducing agent (1mL) and
refluxed for 1.5 h. The reactionmixturewas allowed to cool down to
r.t., quenched with water (0.1mL) followed by 6M aqueous HCl
(1mL). A complex of a boron and 2i was detected by MS, which
dissociated on reflux of the mixture for 10min (followed by MS).
The resulting solution was evaporated to dryness, the residue dis-
solved in MeOH and purified by C18 RP flash chromatography and
lyophilized to give the title derivative (2i) as light brown powder
(0.038 g, 45%, TFA salt). 1H NMR (400MHz, Methanol-d4) d 8.17 (dd,
J¼ 18.3, 8.2 Hz, 4H), 7.64 (dt, J¼ 15.1, 7.0 Hz, 4H), 7.56e7.31 (m, 2H),
7.29e7.00 (m, 2H), 3.75 (dAB, J¼ 15.1 Hz, 2H), 3.68 (dAB, J¼ 15.1 Hz,
2H), 3.24 (t, J¼ 6.4 Hz, 2H), 3.13 (s, 2H), 2.86 (t, J¼ 6.4 Hz, 2H). 13C
NMR (101MHz, Methanol-d4) d 176.7, 159.5 (d, J¼ 250.9 Hz), 135.6
(d, J¼ 4.2 Hz), 129.4 (d, J¼ 8.5 Hz), 129.0 (d, J¼ 4.4 Hz), 128.5, 127.3
(d, J¼ 1.9 Hz), 125.5 (d, J¼ 2.6 Hz), 125.2 (d, J¼ 15.9 Hz), 121.9 (d,
J¼ 6.1 Hz), 109.8 (d, J¼ 20.2 Hz), 51.6, 44.3, 40.4, 38.7, 36.9. m/z:
C27H28F2N3O [MþH]þ calculated for 448.2195, found: 448.2194.
3-Amino-1-(2-aminoethylamino)-2,2-bis[(1-naphthyl)methyl]-1-
propanone (2j). One spoon of Raney-Nickel (approx. 5 g) was
transferred to a round bottomed flask, washed with MeOH
(3 15mL) and EtOAc (3 15mL) before addition of compound 1i
(0.114 g, 0.25mmol) dissolved in EtOAc. Boc2O (0.224 g, 1.03mmol,
4 equiv.) was added. The reactionwas stirred for 18 h at 45 Cwith a
H2(g) containing balloon attached. The reactionmixture was cooled
to r.t. before the catalyst was filtered off through a pad of sand and
celite under N2, washed with brine, dried with Na2SO4, and evap-
orated to dryness. The Boc-protected intermediate was added
dioxane (4mL), H2O (0.5mL), and 4M HCl/dioxane (2mL) to yield
the crude HCl-salt. The product was purified by C18 RP flash chro-
matography. 1H NMR (400MHz, Methanol-d4) d 7.90e7.82 (m, 6H),
7.75 (d, J¼ 1.7 Hz, 2H), 7.56e7.46 (m, 4H), 7.38 (dd, J¼ 8.4, 1.8 Hz,
2H), 3.53 (t, J¼ 6.5 Hz, 2H), 3.42 (d, J¼ 14.2 Hz, 2H), 3.20 (d,
J¼ 14.1 Hz, 2H), 3.12e3.08 (m, 4H). 13C NMR (101MHz, Methanol-
d4) d 177.1, 134.8, 134.1, 134.0, 130.4, 129.4, 129.3, 128.7, 128.7, 127.5,
127.2, 51.0, 43.8, 41.4, 40.6, 38.7. HRMS-ESIm/z: C27H30N3O [MþH]þ
calculated for 412.2382, found: 412.2394.
Preparation of triamine derivatives 3. Derivatives 3d, 3e, 3g, and
3i were prepared in accordance to the procedure for nitrile
reduction of 2i with ZnCl2/NaBH4, but with 24 h reaction time [32].
3-Amino-1-(2-aminoethylamino)-2,2-bis[(o-bromophenyl)
methyl]propane (3d). The nitrile 1d (0.985mmol, 0.455 g) and the
ZnCl2/NaBH4 reducing agent (7.0mL) gave the title derivative (3d)
as clear crystals (HCl-salt) after purification by C18 RP flash chro-
matography with acetonitrile/water and lyophilized with aq. HCl
(0.123 g, 22%). 1H NMR (600MHz, DMSO‑d6) d 10.04 (s, 2H), 8.66 (s,
3H), 8.44 (s, 3H), 7.66 (d, J¼ 8.1 Hz, 2H), 7.51 (d, J¼ 7.6 Hz, 2H), 7.43
(t, J¼ 7.6 Hz, 2H), 7.26 (t, J ¼ 7.8 Hz, 2H), 3.39 (s*, 2H), 3.36(s*, 2H),
3.31 (d*, J¼ 14.6 Hz, 2H), 3.25 (d*, J¼ 14.9 Hz, 2H), 2,97 (s*, 2H), 2.91
(s*, 2H). * Extensive line broadening due to conformational ex-
change. 13C NMR (151MHz, DMSO‑d6) d 134.8, 133.3, 133.0, 129.4,
128.0, 125.9, 50.2, 46.3, 42.4, 41.3, 36.2, 35.2. HRMS-ESI m/z:
C19H2679Br2N3 [MþH]þ calculated for 454.0486, found: 454.0495.
3-Amino-1-(2-aminoethylamino)-2,2-bis[(3,5-dibromophenyl)
methyl]propane (3e). The nitrile 1e (0.33mmol, 0.205 g) and the
reducing agent (3.0mL) gave the title derivative (3e) as clear
crystals after purification (TFA-salt) (0.068 g, 22%). 1H NMR
(400MHz, Methanol-d4) d 7.69 (s, 2H), 7.44 (s, 4H), 3.15 (t,
J¼ 6.4 Hz, 2H), 3.06 (s, 2H), 2.96 (t, J¼ 6.4 Hz, 2H), 2.88e2.68 (m,
6H). 13C NMR (101MHz, Methanol-d4) d 141.4, 134.0, 133.7, 124.1,55.6, 48.3, 46.8, 40.8, 40.5, 39.7. HRMS-ESI m/z: C19H2479Br4N3
[MþH]þ calculated for 609.8694, found: 609.8719.
3-Amino-1-(2-aminoethylamino)-2,2-bis([3,5-
bis(trifluoromethyl)phenyl]methyl) propane (3g). The nitrile 1g
(0.18mmol, 0.104 g) and the reducing agent (2.7mL) gave the title
derivative (3g) as clear crystals after purification (TFA-salt) (0.061 g,
37%). 1H NMR (400MHz, Methanol-d4) d 1H NMR (400MHz,
Methanol-d4) d 7.92 (s, 2H), 7.88 (s, 4H), 3.10 (s, 4H), 3.04 (dAB,
J¼ 13.8 Hz, 2H), 2.93 (dAB, J¼ 13.6 Hz, 2H), 2.87 (t, J¼ 6.0 Hz, 2H),
2.74 (s, 2H). 13C NMR (101MHz, Methanol-d4) d 140.3, 132.9 (q,
J¼ 33.1 Hz), 132.37e132.14 (m), 124.8 (q, J¼ 272.0 Hz), 122.2 (h,
J¼ 3.7 Hz), 55.9, 48.3 (overlap with solvent, confirmed by HSQC),
47.2, 40.8, 40.7, 40.0. HRMS-ESI m/z: C23H24F12N3 [MþH]þ calcu-
lated for 570.1774, found: 570.1766.
3-Amino-1-(2-aminoethylamino)-2,2-bis[(4-fluoro-1-naphthyl)
methyl]propane (3i). The nitrile 1i (0.33mmol, 0.145 g) and the
reducing agent (3.0mL) gave the title derivative (3i) as clear crys-
tals (TFA-salt) after purification (0.093 g, 36%). 1H NMR (400MHz,
Methanol-d4) d 8.14 (dt, J¼ 6.3, 2.7 Hz, 2H), 8.05e7.89 (m, 2H), 7.58
(dd, J¼ 6.5, 3.1 Hz, 4H), 7.40 (t, J¼ 6.7 Hz, 2H), 7.23 (td, J¼ 9.2, 8.0,
2.3 Hz, 2H), 3.47e3.25 (m, 10H), 3.20 (s, 2H), 3.04 (t, J¼ 5.9 Hz, 2H),
2.93 (s, 2H), 2.84 (t, J¼ 5.6 Hz, 2H). 13C NMR (101MHz, Methanol-
d4) d 159.5 (d, J¼ 251.1 Hz), 135.8 (d, J¼ 4.2 Hz), 129.8 (d, J¼ 8.4 Hz),
129.6 (d, J¼ 4.8 Hz), 128.5, 127.4 (d, J¼ 1.9 Hz), 125.47e125.20 (m),
125.4 (d, J¼ 2.8 Hz), 122.1 (d, J¼ 6.2 Hz), 109.9 (d, J¼ 20.1 Hz), 56.5,
48.3, 47.7, 42.9, 39.8, 36.3. HRMS-ESI m/z: C27H30F2N3 [MþH]þ
calculated for 434.2402, found: 434.2420.
Preparation of guanidine derivatives 4. Derivatives 4e, 4g, and 4i
were prepared using the following procedure: To a stirred solution
of the salt of 2e (HCl), 2g (HCl) or 2i (TFA) in THF, K2CO3 was added
followed by N,N0-Di-Boc-1H-pyrazole-1-carboxamidine. The reac-
tion was stirred at r.t. for 48e72 h. The reaction mixture was
concentrated, the crude product was dissolved in EtOAc and
washed with water and brine. The organic phase was dried over
Na2SO4, filtered and concentrated. The crude product was purified
by automated flash chromatography (EtOAc/Heptane) and the
resulting Boc-protected intermediate was deprotected with TFA
(1mL) in CH2Cl2 (1:1) for 18 h. The reaction mixture was concen-
trated and the crude was purified by RP automated flash chroma-
tography (ACN/water 0,1% TFA) and lyophilized to yield the
guanylated product.
2,2-bis(3,5-dibromobenzyl)-3-guanidino-N-(2-guanidinoethyl)
propenamide (4e). The HCl salt of 2e (120mg, 0.17mmol, 1 equiv.)
was dissolved in THF (5mL) and added K2CO3 (118mg, 0.85mmol,
5 equiv.) andN,N0-Di-Boc-1H-pyrazole-1-carboxamidine (221mg, 4
equiv.) and stirred for 72 h. The reaction mixture was then treated
according to the general procedure to yield the title compound 4e
as a white powder (TFA-salt, 55mg, 34%). 1H NMR (400MHz,
Methanol-d4) d 7.67 (t, J¼ 1.7 Hz, 2H), 7.32 (d, J¼ 1.7 Hz, 4H),
3.45e3.39 (m, 2H), 3.37e3.32 (m, 2H), 3.21 (dAB, J¼ 14.0 Hz, 2H),
3.10 (s, 2H), 2.91 (dAB J¼ 14.1 Hz, 2H). 13C NMR (101MHz, Meth-
anol-d4) d 175.6, 158.9, 158.9, 141.4, 134.0, 133.0, 124.0, 52.6, 43.8,
42.1, 41.3, 40.1. HRMS-ESI m/z: [MþH]þ calculated for
C21H2679Br4N7Oþ 707.8926, found: 707.8947.
2,2-bis(3,5-bis(trifluoromethyl)benzyl)-3-guanidino-N-(2-
guanidinoethyl)propenamide (4g). The HCl salt of 2g (34mg,
0.052mmol, 1 equiv.) was dissolved in THF (3mL) and added K2CO3
(35mg, 0.25mmol, 5 equiv.) and N,N0-Di-Boc-1H-pyrazole-1-
carboxamidine (66mg, 0.21mmol, 4 equiv.) and stirred for 72 h.
The reaction mixture was then treated according to the general
procedure to yield the title compound 4e as a white powder (TFA-
salt, 17mg, 37%). 1H NMR (400MHz, Methanol-d4) d 7.91 (s, 2H),
7.75 (s, 4H), 3.49 (dAB, J¼ 14.2 Hz, 2H), 3.41e3.35 (m, 2H),
3.34e3.32 (m, 2H), 3.19 (dAB, J¼ 14.2 Hz, 2H), 3.08 (s, 2H). 13C NMR
(101MHz, Methanol-d4) d 175.0, 162.9 (q, J¼ 35.6 Hz, TFA), 159.1,
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J¼ 272.0 Hz), 122.5e122.2 (m), 118.0 (q, J¼ 292.0 Hz, TFA), 52.7,
43.8, 41.6, 41.3, 40.1, 31.7. HRMS-ESI m/z: [MþH]þ calculated for
C25H26F12N7Oþ 688.2003, found: 668.2005.
3-(4-fluoronaphthalen-1-yl)-2-((4-fluoronaphthalen-1-yl)
methyl)-N-(2-guanidinoethyl)-2-(guanidinomethyl)propenamide
(4i).The TFA salt of 2i (25mg, 0.037mmol,1 equiv.) was dissolved in
THF (2mL) and added K2CO3 (20mg, 0.14mmol, 4 equiv.) and N,N0-
Di-Boc-1H-pyrazole-1-carboxamidine (32mg and an extra 15mg
after 24 h, 0.15mmol, 4 equiv.). The reaction mixture was then
treated according to the general procedure to yield the title com-
pound 4i as a light brown powder (TFA-salt, 13mg, 46%). 1H NMR
(400MHz, Methanol-d4) d 8.22e8.17 (m, 2H), 8.12 (dd, J¼ 8.1,
1.7 Hz, 2H), 7.66e7.56 (m, 4H), 7.35 (dd, J¼ 8.1, 5.4 Hz, 2H), 7.15 (dd,
J¼ 10.3, 8.0 Hz, 2H), 3.71 (dAB, J¼ 15.2 Hz, 2H), 3.62 (dAB,
J¼ 15.2 Hz, 2H), 3.36 (s, 2H), 3.07 (t, J¼ 6.4 Hz, 2H), 2.94 (t,
J¼ 6.4 Hz, 2H). 13C NMR (101MHz, Methanol-d4) d 176.8, 159.4 (d,
J¼ 250.8 Hz), 158.8, 158.7, 135.5 (d, J¼ 4.2 Hz), 129.6 (d, J¼ 4.7 Hz),
128.9 (d, J¼ 8.4 Hz), 128.3, 127.3 (d, J¼ 1.9 Hz), 125.6e124.8 (m),
121.9 (d, J¼ 6.2 Hz), 109.7 (d, J¼ 20.0 Hz), 52.6, 45.6, 41.6, 39.9, 37.7.
HRMS-ESI m/z: [MþH]þ calculated for C29H32F2N7O2þ 532.2631,
found: 532.2631.
4.3. Biological test methods
Minimum inhibitory concentration (MIC) assay: Stock solutions
of the test derivatives were prepared with up to 100% DMSO and
stored at 20 C. If necessary, the solutions were heated to
40e80 C before testing to facilitate complete dissolution. Double-
distilled water was used in all dilutions prepared. The final con-
centration of DMSO in the test series was 1% and did not affect
the assay results. A microdilution susceptibility test was used for
MIC determination according to CLSI M07-A9 [43] with modifi-
cations as described by Igumnova et al. [44]. Briefly, the bacterial
inoculum was adjusted to approximately 2.5e3 x 104 cells/mL in
Mueller-Hinton broth (MHB, Difco Laboratories, USA), and incu-
bated in a ratio of 1:1 with test derivatives in polystyrene 96-well
flat-bottom microplates (NUNC, Roskilde, Denmark). Positive
growth control (without test derivatives) and negative control
(without bacteria) were included. The reference antibiotic was
oxytetracycline hydrochloride (Sigma Aldrich, Saint Louis, MO,
USA). The microplates were placed in an incubator set to 37 C
(20 C for C. glutamicum) for 24 h. The MIC value was defined as
the lowest concentration of derivative resulting in no bacterial
growth as determined by OD600 measurement using a Synergy H1
Hybrid Multi-Mode micro plate reader (BioTek Instruments Inc.,
Winooski, VT, USA). All derivatives were tested in three parallels.
Antimicrobial screening against clinical isolates: The Norwegian
National Advisory Unit on Detection of Antimicrobial Resistance (K-
res), University Hospital of Northern-Norway (UNN), provided the
collection of 30 multi-drug resistant isolates in Table 2. The MIC
was determined as explained above with some exceptions; work-
ing solutions of test derivatives were prepared from concentrated
DMSO stocks stored at r.t., the density of the bacterial inoculumwas
increased 40 x to 1e1.2 106 cells/mL, enterococci were incubated
in Brain Heart Infusion broth (BHIB, Difco Laboratories, USA), the
microplates were incubated for 24 h, and the derivatives were
tested in four parallels. Also, in this assay, optical density (OD) is
proportional to the amount of bacteria and should be equal to the
OD of the control when bacterial growth is completely inhibited.
However, for some compounds the OD was not reduced to the
control level even though complete inhibition was expected due to
the stepwise increase in concentration. The remaining ODmight be
explained by precipitation of compounds and media components,
residues of bacterial culture, etc. Thus, the term “inhibitoryconcentration” (IC) is used to define the point where a major
decrease of OD is observed. The IC should reflect the impact of
tested compounds on bacteria and correlate with the MIC.
Determination of haemolytic activity: The protocol was adapted
from Tørfoss et al. [45]. In brief, a heparinizied fraction (10 USP
units/mL) human blood was used for haemolysis determination
whereas a second fraction in test tubes containing EDTA (Vacut-
est®, KIMA, Arzergrande, Italy) was used for determination of the
hematocrit (hct). Plasma was removed from the heparinized blood
bywashing three times with pre-warmed PBS before adjustment to
10% hct. Stock solutions of derivatives in DMSO were dissolved in
PBS with a final DMSO content 1%. The positive control for 100%
haemolysis consisted of 1% Triton X-100 (Sigma-Aldrich). A nega-
tive control containing 1% DMSO in PBS buffer was included and no
signs of toxicity were detected. Test solutions and erythrocytes (1%
v/v final concentration) were mixed and incubated under agitation
at 37 C for 1 h. After centrifugation, 100 mL of each reaction vial
were transferred to a 96-well plate in triplicate and diluted with
PBS if necessary. Absorbance was recorded with a microplate
reader (VersaMax™, Molecular Devices, Sunnyvale, CA, USA), at
405 nm and 545 nm. After subtracting PBS background, the per-
centage of haemolysis was calculated as the ratio of the absorbance
in the derivative-treated and surfactant-treated samples. Experi-
ments were performed in three independent replicates and EC50
values are reported as an average.
Determination of cytotoxicity: Cytotoxicity was studied using
HepG2 cells (human liver carcinoma) and MRC-5 cells (human lung
fibroblasts). The cells were seeded at 35 000 and 15 000 cells per
well respectively. The cells were incubated at 37 C, 5% CO2 over-
night. Test compounds diluted in MEM Earle's without FBS were
added to the cells and incubated for 4 h. After incubation, 10 mL of
CellTiter 96® AQueous One Solution Reagent (Promega, Madison,
WI, USA) was added and the plates were then incubated further for
1 h. Absorbance was measured at 485 nm using a DTX 880 Multi-
mode Detector. Results were calculated as % survival compared to
negative (assay media) and positive (Triton X-100; Sigma-Aldrich)
control.
pKa predictions: The 2D structures of compounds monoamine
1e, diamine 2e, triamine 3e, and diguanidine 4e (in ChemDraw.cdx
format) were imported into the Schr€odinger software suite
(2018e4 release) via the Maestro interface, and then prepared for
further calculations using the LigPrepmodule [46]. The resulting 3D
structures (neutral form) were then subjected to pKa prediction at
pH 7.4 (solvent¼H2O) using the «sequential mode» of the Epik
program [33,47]. In contrast to a standard pKa prediction, where
the pKa of the individual functional groups are calculated, the
sequential method removes/adds protons from/to the pH adjusted
structure, and recalculates the pKa values after each step, which
means that the effect of sequential ionization is taken into
consideration in the pKa predictions.
4.4. Phase I metabolism
The murine liver microsomes (M9066, male rat, Sprague-
Dawley) where purchased from Sigma-Aldrich. The derivatives
investigated were all >95% pure as determined by reversed-phase
(RP) high performance liquid chromatography (HPLC) with ultra-
violet (UV) detection at 214 and 254 nm. Lidocaine was chosen as
the positive control since its functional groups resembles the
structure of the derivatives investigated. Lidocaine was synthesized
in house. Acetonitrile and methanol were purchased from Sigma-
Aldrich. Water was obtained from a Milli-Q rinsing system from
Millipore.
Microsome incubations: The procedure for monitoring metabolic
stability by murine liver microsomes was performed according to
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phosphate buffer (100mM, pH 7.4), 6 mL of freshly made NADPH
regenerating system (consisting of 1.3mM NADP, 3.3mM glucose-
6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase,
3.3mMmagnesium chloride in 100mM phosphate buffer (pH 7.4)),
and 1 mL of a newly thawed aqueous stock solution of substrate
(100 mM) were added to 1.5mL Eppendorf tubes. The tubes were
centrifuged at low speed (2 s) and vortexed (5 s, medium strength)
and placed in crushed ice while the liver microsomes solution
(pooled frommale SpragueeDawley rats, 20mg/mL) was thawed in
a 37 C water bath. Immediately after thawing and vortexing, 2.5 mL
of microsomes was added each sample following centrifuging (2 s)
and vortexing (5 s) and transferred to a 37 C water bath (total
sample volume 99.5 mL). The incubation tubes were quenched at
given time points with 50 mL ice-cold methanol containing an in-
ternal standard (0.3 mg/mL propranolol hydrochloride), capped,
vortexed, and put on ice for 1 h. The time points for 2e, 2g, and 2i
were 0, 5,10,15, 25, 45, 60 and 180min, and for lidocaine 0, 5,10, 25
and 40min. The tubes were centrifuged at 13 000 rpm for 3min at
4 C. An aliquot of each sample (100 mL) were analysed by RP-HPLC
and high-resolution mass spectrometry (HRMS). The control sam-
ples containing the derivative in question and the derivative plus
the regenerating system were quenched at 180min. The experi-
ments were run in triplicates, and the quantification was run in
duplicates. The samples were analysed within 24 h after
preparation.
Calibration curves and recovery: Calibration curves were ob-
tained for all derivatives from standard solutions in the concen-
tration range 0.25e12.5 mM. The standard solutions were prepared
using Milli-Q water as diluent. The calibration curves were pre-
pared and run subsequently after the samples.
RP-HPLC analysis: The RP-HPLC analysis was performed using
a Thermo Fischer Accela autosampler and a SunFire (Waters) TM
2.1 50 mm, 2.5 mm dP, C18 column coupled to an Accela pump.
The column heater was set to 40 C and the autosampler at 4 C.
The mobile phase consisted of A (0.1% formic acid in Milli-Q
water) and B (0.1% formic acid in acetonitrile). The following
composition was used: 2% B for 2min; a linear gradient of 2e50%
B over 3min; then 90% B for 1min) The injection volume was
5 mL and the flow rate 400 mLmin1. Flow was directed to waste
at 0e1.5min.
Mass spectrometry analysis of metabolites: A Thermo LTQ Orbi-
trap XL mass spectrometer was coupled to the RP-HPLC through an
electrospray ionization (ESI) interphase and operated in the posi-
tive ion mode for quantitative analysis. The instrument was oper-
ated in full scan mode for quantitative determination of the
substrates 2e, 2g, 2i and lidocaine and semi-quantitative determi-
nation of their corresponding metabolites. For detection of the
metabolites in the incubated samples the instrument was operated
in full scan mode with mass range of 125 or 130 to 700 (m/z)
(resolution 30 000). The detected metabolites were further ana-
lysed by targeted MS2 scan with higher-energy collisional dissoci-
ation (HCD) fragmentation at 35 eV (resolution 7500). The
following settings were used for the analyses: Sheath gas flow rate
70, auxiliary gas flow rate 10, sweep gas flow rate 10, spray voltage
4.5 kV, capillary temperature 330 C, capillary voltage 37 V, and
tube lens 80 V.
Statistical treatment of the data: Percentage of remaining de-
rivatives were calculated based on the area under the curve (single
ion chromatogram, protonated molecular ion) for the derivatives
compared to the internal standard. Average and standard de-
viations were calculated based on the concentrations. Response
factor of the metabolites were assumed to be equal to the un-
metabolised derivatives, hence enabling a semi-quantitation of
the metabolites.Acknowledgments
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